Selected article for: "antiviral activity and cov infection"
Author: Nau, Jeffrey; Luthra, Priya; Lanzer, Kathleen; Szaba, Frank; Cookenham, Tres; Carlson, Eric
Title: Varenicline Prevents SARS-CoV-2 Infection In Vitro and in Rhesus Macaques
  • Cord-id: 9ktbr62c
  • Document date: 2021_6_30
    • ID: 9ktbr62c
    Snippet: Background SARS-CoV-2 infections have resulted in a global pandemic, but an antiviral therapy for this novel strain of coronavirus does not currently exist. The objective of our study was to investigate the antiviral potential of the nicotinic acetylcholine receptor (nACHR) agonist varenicline tartrate against SARS-CoV-2. Methods We assessed antiviral activity using in vitro human cell assays and we assessed in vivo efficacy in a rhesus macaque model. Results In vitro studies found that varenicl
    Document: Background SARS-CoV-2 infections have resulted in a global pandemic, but an antiviral therapy for this novel strain of coronavirus does not currently exist. The objective of our study was to investigate the antiviral potential of the nicotinic acetylcholine receptor (nACHR) agonist varenicline tartrate against SARS-CoV-2. Methods We assessed antiviral activity using in vitro human cell assays and we assessed in vivo efficacy in a rhesus macaque model. Results In vitro studies found that varenicline tartrate, over a range of concentrations, reduced the infectivity of SARS-CoV-2 wildtype, alpha, and beta variants in Calu-3 cells and Caco-2 cells, with maintenance of cell viability. In vivo studies found that varenicline tartrate, administered as a nasal spray to rhesus macaques, reduced SARS-CoV-2 wildtype viral load and inhibited viral replication in the nasal mucosa and upper airway. Conclusion Although the study reported here was exploratory, we have confirmed that the nAChR agonist varenicline has the potential to interact with and inhibit SARS-CoV-2 infection and replication.

    Search related documents:
    Co phrase search for related documents
    • abstract background and additional study: 1, 2
    • acetylcholine receptor and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • acetylcholine receptor and lung inflammation: 1, 2, 3
    • active ingredient and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • active ingredient and additional study: 1
    • active ingredient and lung inflammation: 1, 2
    • acute respiratory syndrome and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and load analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • acute respiratory syndrome and low upper respiratory: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory syndrome and low upper respiratory tract: 1, 2, 3, 4, 5
    • acute respiratory syndrome and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and macaque model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
    • load analysis and lung inflammation: 1